• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharma (NQ: ARWR )

    24.44 +0.31 (+1.28%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 630,822
    Open 25.03
    Bid (Size) 24.11 (2)
    Ask (Size) 25.50 (5)
    Prev. Close 24.13
    Today's Range 24.12 - 25.23
    52wk Range 20.67 - 42.48
    Shares Outstanding 105,736,200
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
    Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... 
    Via Benzinga
    Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -21.19%
    -21.19%
    1 Month
    -6.68%
    -6.68%
    3 Month
    -24.08%
    -24.08%
    6 Month
    -6.57%
    -6.57%
    1 Year
    -39.20%
    -39.20%

    More News

    Read More
    Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma
    Via Benzinga
    Recap: Arrowhead Pharma Q1 Earnings
    Via Benzinga
    Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Turnstone Biologics Appoints William Waddill to its Board of Directors
    From Turnstone Biologics Corp.
    Via GlobeNewswire
    Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
    Via InvestorPlace
    NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
    Via Benzinga
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    7 Biotech Stocks to Buy as Sector Rotation Ramps Up
    Via InvestorPlace
    The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
    Via InvestorPlace
    EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    7 Oversold Russell 2000 Stocks to Add to Your February Buy List
    Via InvestorPlace
    Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
    Via Investor's Business Daily
    7 Biotech Stocks Fighting America’s Deadliest Diseases
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.